Overview: HIV 1 and 2 Antibody Screen TestIntroduction: The HIV 1 and 2 Antibody Screen Test screens for HIV-1 and HIV-2 antibodies to diagnose infection, causing fever or weight loss. Following 2023 CDC guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antiretroviral therapy, and improving outcomes in serology for patients with suspected HIV/AIDS, ensuring early intervention to prevent progression.
Other Names: HIV 1&2 Ab Assay, HIV Screening Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: HIV antibody testing began in the 1980s with the AIDS epidemic. Immunoassays improved in the 2000s, enhancing screening sensitivity.
Purpose: Diagnoses HIV infection, guides antiretroviral therapy, and monitors HIV-1 and HIV-2 antibodies in patients with fever or weight loss.
Test Parameters: 1. HIV 1 & 2 Antibodies
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like fever, weight loss, or night sweats, and list medications or risk factors (e.g., IV drug use).
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, weight loss, night sweats, or history of HIV exposure. Include current medications, risk factors (e.g., unprotected sex), and recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiretroviral therapy or counseling.
Procedural Considerations: Uses an immunoassay to detect HIV-1 and HIV-2 antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often as a screening tool.
Factors Affecting Result Accuracy: Improper sample handling or early infection can affect results. False positives may occur in low-risk populations, requiring confirmatory testing.
Clinical Significance: Positive antibodies indicate HIV infection, prompting confirmatory testing (e.g., HIV RNA). Negative results may require repeat testing in early infection.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and antiretroviral therapy planning.
Additional Supporting Tests: HIV RNA PCR, Western blot, or CD4 count to confirm HIV infection and assess disease status.
Test Limitations: False negatives may occur in early infection (window period). Confirmatory testing is essential.
References: CDC HIV Guidelines, 2023; Clinical Infectious Diseases, Branson BM, 2022.
